Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)

Launched by STANFORD UNIVERSITY · Feb 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to see how effective a treatment is for patients with Glioblastoma (GBM), a type of brain tumor. Researchers want to find out if a special imaging technique, called DMI, can help predict how well a new medication, BPM31510, works when added to the standard treatment for GBM. BPM31510 is a form of CoQ10, which is a natural substance that helps cells produce energy, delivered in a special way to improve its effectiveness.

To participate in the trial, you need to be between 65 and 74 years old and agree to take part in the study. Women who could become pregnant must have a negative pregnancy test and be willing to provide written consent. However, if you refuse to have an IV, have allergies to certain MRI contrasts, or are a diabetic patient using insulin, you won't be eligible for this trial. If you join, you'll undergo imaging tests to see how the medication is working and help researchers learn more about treating GBM.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Any participant that consents to entry into the Phase II BPM31510 parent study (BPM31510IV-11)
• • Women of childbearing potential must have a negative pregnancy test
• • Ability to understand and the willingness to provide written informed consent.
• Exclusion Criteria:
• • Refuse to have an IV
• • Allergy to MRI contrasts
• • Diabetic patients who are taking insulin